Developing a new vaccine to prevent respiratory infections caused by RSV
Novel G protein-based RSV vaccine
This study is working on a new vaccine to help protect babies and older adults from respiratory syncytial virus (RSV), which can cause serious breathing problems, and if it works well, it could really lower the number of people getting sick from this virus.
Quick facts
| Grant type | Sbir 2 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Sciogen, LLC NIH-funded |
| Lab location | 1 site (San Jose, UNITED STATES) |
| Project ID | NIH-11060069 on NIH RePORTER |
What this research studies
This research focuses on creating a novel vaccine targeting respiratory syncytial virus (RSV), which is a major cause of respiratory illness in infants and the elderly. The approach involves using a G protein-based vaccine that has shown promising results in animal models, providing complete protection against RSV without causing enhanced disease. The research will include developing the vaccine further through various evaluations, including maternal immunization and safety studies. If successful, this vaccine could significantly reduce the incidence of RSV-related respiratory infections.
Who could benefit from this research
Good fit: Ideal candidates for this research include infants under 11 years old and elderly individuals who are at higher risk for RSV-related respiratory illnesses.
Not a fit: Patients who are not in the targeted age groups or those with existing severe respiratory conditions may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to a safe and effective vaccine that prevents severe respiratory infections in vulnerable populations, particularly infants and the elderly.
How similar studies have performed: Previous research has shown some success with G protein-based vaccines in animal models, but this approach is still relatively novel in human studies.
Where this research is happening
San Jose, UNITED STATES
- Sciogen, LLC — San Jose, United States (Active)
Researchers
- Principal investigator: Li, Shengqiang — Sciogen, LLC
- Study coordinator: Li, Shengqiang
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.